These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1751924)

  • 1. Generic drug companies are the winners.
    Voth AJ
    CMAJ; 1991 Nov; 145(9):1081. PubMed ID: 1751924
    [No Abstract]   [Full Text] [Related]  

  • 2. Supreme Court rules against drug patent "evergreening".
    Kondro W
    CMAJ; 2006 Dec; 175(12):1508-9. PubMed ID: 17146081
    [No Abstract]   [Full Text] [Related]  

  • 3. Generic drugs go to market. Effective, safe and less expensive.
    Mayo Clin Health Lett; 2006 Sep; 24(9):4-5. PubMed ID: 17139760
    [No Abstract]   [Full Text] [Related]  

  • 4. [What drug companies actually do].
    Tonby K
    Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137
    [No Abstract]   [Full Text] [Related]  

  • 5. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 6. [Why patent-protected drugs' cost efficiency should be compared with generic preparations].
    Berggren F; Lundin D; Ramsberg J
    Lakartidningen; 2006 Jan 25-31; 103(4):223-4. PubMed ID: 16491555
    [No Abstract]   [Full Text] [Related]  

  • 7. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 8. Reforming Canada's Access to Medicines Regime.
    Elliott R
    CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of United States and Canadian laws as they affect generic pharmaceutical market entry.
    Hore E
    Food Drug Law J; 2000; 55(3):373-88. PubMed ID: 11824466
    [No Abstract]   [Full Text] [Related]  

  • 10. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products.
    Becker C
    Mod Healthc; 2001 Aug; 31(35):28-33, 1. PubMed ID: 11550428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attempt to sell generic version of zidovudine angers brand name company, researchers.
    Spurgeon D
    CMAJ; 1992 Aug; 147(3):332-4. PubMed ID: 1643599
    [No Abstract]   [Full Text] [Related]  

  • 12. The generic drug approval process.
    Rheinstein PH
    Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
    [No Abstract]   [Full Text] [Related]  

  • 13. Indian biogenerics industry emerges.
    Jayaraman KS
    Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
    [No Abstract]   [Full Text] [Related]  

  • 14. Statin utilisation--recognising the role of the invisible hand.
    Minhas R
    Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
    [No Abstract]   [Full Text] [Related]  

  • 15. Canadian hopes for low-cost drugs dashed.
    Kondro W
    Lancet; 1998 Jan; 351(9099):350. PubMed ID: 9652632
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 17. Lowering the cost of prescription drugs.
    Jindal B
    J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug patent protection: how long is long enough?
    Sibbald B
    CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
    [No Abstract]   [Full Text] [Related]  

  • 19. Epo, by any other name.
    Nature; 2007 Sep; 449(7160):259. PubMed ID: 17882170
    [No Abstract]   [Full Text] [Related]  

  • 20. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry.
    Burshtein S
    Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.